drugset / Trial / NCT01430559

Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee

NCT01430559

Completed 408 enrolled Pfizer
RandomizedParallel-groupDouble-blindOther

Summary

This study is to validate the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) tool in mainland Chinese patients with osteoarthritis of the knee . This study will also evaluate the effects of Mobic versus placebo on reducing the symptoms of osteoarthritis in this population.

Timeline

Start
2011-10-24
Primary completion
2013-03-27
Completion
2013-03-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Meloxicam Small molecule 15 mg

Indications